Vitalis to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Tuesday, September 1st, 2020 8:00 am ET
NEW YORK, Sept. 1, 2020 (GLOBE NEWSWIRE) -- Vitalis LLC, a specialty pharmaceutical company leveraging its proprietary VTS platform to overcome the limitations of existing drugs and enhance patient experience across a variety of therapeutic areas including multiple sclerosis and post-operative pain, today announced Joseph Habboushe, M.D., MBA., Chief Executive Officer and founder, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 3:00 p.m. Eastern Time.
A live audio webcast of the presentation can be accessed through the Media section of the Company's website at https://www.vitalispharma.com/. A replay of the webcast will be available on the Company's website following the live presentation.
Vitalis is a privately-held specialty pharmaceutical company focused on overcoming the limitations of existing drugs using its proprietary VTS-Aspirin platform. Its most advanced product, VTS-72, uniquely combines aspirin with fumaric acid, the leading multiple sclerosis medication, to reduce its most common side effect while improving pharmacokinetics. Similarly, its second candidate, VTS-K, may be the first oral ketamine to enter the market, aiming to reduce opioid need while supplanting injectable blood thinners after joint replacements. For additional information, please visit www.vitalispharma.com.
Burns McClellan for Vitalis Pharmaceuticals
Lee Roth (Investors) / Ryo Imai (Media)